About tildrakizu mab
Interleukin-23 (IL-23) inhibitor
Used for
- Treats moderate-to-severe plaque psoriasis in adults who may benefit from systemic treatment or phototherapy.
Usual adult dose
100 mg injected under the skin at weeks 0 and 4, then every 12 weeks.
Common side effects
- Upper respiratory infections
- Injection-site reactions
- Diarrhea
- Headache
Important warnings
- Check for tuberculosis before treatment; treat active tuberculosis first.
- Avoid live vaccines during treatment.
- Serious allergic reactions can occur.
- Treatment may increase infection risk.
Pregnancy
Human pregnancy data are limited; use during pregnancy only when clearly needed.
Breastfeeding
It is unknown whether tildrakizumab passes into breast milk; discuss potential risks with a clinician.
Interactions
- Live vaccines may be less safe or effective during treatment.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.